कंपनी का अवलोकन
CorMedix Inc. operates as a biopharmaceutical entity dedicated to the research, development, and commercialization of therapeutic solutions for critical diseases and medical conditions within the United States market. The company functions within the healthcare sector, specifically the biotechnology industry, which focuses on applying biological processes and organisms to create products for health and medicine. With a total market capitalization of $581.81M and annual revenue of $311.71M, CorMedix demonstrates a significant presence in the specialized biotechnology landscape. The organization employs 191 individuals to execute its strategic initiatives, indicating a mid-sized operational scale that allows for focused innovation without the overhead of massive corporate structures. These financial dimensions suggest the company holds a substantial valuation relative to its revenue stream, reflecting high market expectations for its pipeline of therapeutic products.
वित्तीय स्वास्थ्य
CorMedix reported a trailing twelve-month revenue of $311.71M, generating net income of $162.07M and an EBITDA of $174.89M during the reporting period. The substantial gap between the revenue figure and the net income figure reveals an exceptionally efficient cost structure, where operating expenses and taxes consume only a fraction of total sales. The company produced free cash flow of $108.51M, which signifies strong financial flexibility and the ability to fund operations, repay debt, or pursue acquisitions without relying heavily on external financing. Three distinct margin metrics highlight this profitability: a gross margin of 92.9%, an operating margin of 53.9%, and a profit margin of 52.3%. The gross margin indicates that the cost of goods sold is minimal relative to sales, typical for biopharmaceutical firms with high IP value, while the operating and profit margins demonstrate that the company retains the majority of every dollar earned as operating profit. In terms of leverage, the company holds cash of $148.53M against a total debt obligation of $148.91M, resulting in a debt-to-equity ratio of 36.74. This near-equivalence in cash and debt levels suggests a balanced balance sheet, though the debt-to-equity ratio indicates a leveraged position relative to shareholders' equity. The current ratio stands at 2.11, which indicates robust short-term liquidity and a capacity to cover short-term liabilities more than twice over with available current assets. Furthermore, the Return on Equity is 66.6% and the Return on Assets is 21.2%, metrics that reveal highly effective management in generating returns on the capital invested by shareholders and utilized in asset deployment.
मूल्यांकन आकलन
The valuation metrics present a trailing P/E ratio of 3.61 and a forward P/E of 10.08. The significant difference between these two figures implies that the market anticipates a sharp increase in earnings per share in the coming year compared to current levels. The price-to-book ratio is 1.44, indicating that the stock trades at a moderate premium over its book value, suggesting investors value the company's intangible assets and future growth potential beyond its tangible net worth. Alternative valuation measures include a price-to-sales ratio of 1.87 and an EV/EBITDA of 3.33. These metrics suggest that the company is valued highly relative to its sales, which is common for pre-commercialized biotech firms, while the low EV/EBITDA reflects the high quality of earnings relative to enterprise value. Regarding price volatility, the stock has a 52-week high of $17.43 and a 52-week low of $6.13. Without a specific current price provided in the facts, the valuation context relies on the range between these extremes to gauge recent price action relative to the annual trading band. The beta value is 1.41, which means the stock is expected to be 41% more volatile than the broader market index. This elevated beta indicates that price movements in CorMedix are likely to be amplified during periods of market stress or rally compared to the general equity market.
Growth & Income
The company's financial trajectory shows a revenue growth rate of 312.1% year-over-year while earnings growth stands at -28.3%. This divergence implies that while top-line sales are expanding rapidly, the bottom-line earnings are contracting, possibly due to one-time costs, restructuring charges, or changes in accounting adjustments affecting the net income figure. As a non-dividend payer, CorMedix has a dividend yield of N/A and a payout ratio of 0.0%. This zero payout ratio confirms that the company retains all of its earnings to reinvest into research and development, clinical trials, or commercialization efforts rather than distributing cash to shareholders. The overall growth and income profile is characterized by explosive top-line expansion coupled with a temporary decline in reported earnings and a complete absence of dividend distributions.